search

Active clinical trials for "Hypertriglyceridemia"

Results 11-20 of 248

Effects of Replacing Energy From Solid Fats and Added Sugars (SoFAS) With Avocado

Elevated TriglyceridesHypertriglyceridemia

The objective of this study is to assess the effects of replacing energy from SoFAS with energy from avocado on non-high-density lipoprotein cholesterol (non-HDL-C) and other aspects of the cardiometabolic health profile including fasting lipoprotein lipid and particle concentrations, insulin sensitivity and blood pressure in men and women with elevated triglycerides (TG).

Recruiting37 enrollment criteria

Effects of DHA-NAT on Postprandial Lipidaemia in Healthy Male Subjects

Hypertriglyceridemia

This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of DHA-NAT (C22:6 N-acyl taurine, an endogenous metabolite derived from the omega-3 fatty acid, docosahexaenoic acid) on postprandial plasma triglyceride levels following a high-fat meal.

Recruiting16 enrollment criteria

A Trial to Assess Full-fat or Low-fat Dairy Foods on Insulin Sensitivity, RBC FA's and Other Markers...

Overweight and ObesityElevated Triglycerides

The objectives of this trial are to assess the effects of adding 2 servings/d of either full-fat or low-fat fermented dairy products to the diet, as a replacement for non-dairy foods with macronutrient composition similar to the low-fat fermented dairy condition, on insulin sensitivity, erythrocyte fatty acid profile and other cardiometabolic health markers in metabolically at-risk adults.

Enrolling by invitation31 enrollment criteria

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Hypertriglyceridemia

The purpose of this study is to evaluate the efficacy and safety of ethyl icosapentate in Chinese patients with severe hypertriglyceridemia.

Active43 enrollment criteria

Effect of Silibinin(A) as a Potential Anti-obesity Agent

Overweight and ObesityHypercholesterolemia1 more

Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat. Therefore, the investigators want to carry out the present trial in order to confirm that Silibinin(A) is able to in vivo inhibit pancreatic lipase, which will reduce the fat absorption and therefore will decrease the amount of energy from food intake. Considering that milk thistle has been extensively studied in humans as liver-protector, the investigators consider that the use of human subjects will be of great interest to accelerate the employment of this compound to improve the effectiveness of dietary treatment in overweight/obese subjects.

Active9 enrollment criteria

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and...

HypertriglyceridemiaAtherosclerotic Cardiovascular Disease1 more

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the percentage of participants who achieve different thresholds in fasting TG. Another objective is to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

Active14 enrollment criteria

Insulin and Standard Management in Hypertriglyceridemic Acute Pancreatitis

HypertriglyceridemiaAcute Pancreatitis

To compare the efficacy of infusion containing insulin and infusion without insulin on reduction of triglycerides in acute hypertriglyceridemic pancreatitis

Not yet recruiting5 enrollment criteria

Abnormal Lipids - Causes and Effects

Hypertriglyceridaemia

At target LDL-C levels, apoB100 concentrations will be higher than recommended levels in the following populations: Tertiary centre lipid clinic patients with raised TG treated with statins. Patients with type 2 diabetes treated with statins. Patients with Chronic Kidney disease (CKD) stages 4 and 5 treated with statins. Despite achieving LDL-C and non-HDL-C targets, a significant number of statin-treated patients have residual cardiovascular risk related to raised hsCRP. The relationship between hsCRP and Lp-PLA2 (markers of inflammation) and LDL particle number measured by apoB100 is stronger than that of measured and calculated LDL and non-HDL. In statin treated patients there will be higher levels of hs-CRP and Lp-PLA2 in patients achieving LDL targets but not apo B targets. We hypothesise that non-diabetic patients with severe hypertriglyceridaemia (fasting serum triglyceride >5.5 mmol/l) have evidence of greater nerve damage compared with matched controls. LAL deficiency is underdiagnosed in patients with severe hypertriglyceridaemia, low HDL-C, hyperlipidaemias, non alcoholic fatty liver disease and idiopathic high liver enzymes.

Recruiting14 enrollment criteria

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia...

High Triglycerides

This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment. The two periods consist of: A 3-week screening period that includes a TG qualifying period, and A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period. Subjects will return to the study site for a follow-up visit 2 weeks after the last dose. Approximately 50 subjects will be randomized at approximately 15-20 centres in USA.

Not yet recruiting62 enrollment criteria

Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients...

HypertriglyceridemiaFamilial

The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.

Not yet recruiting32 enrollment criteria
123...25

Need Help? Contact our team!


We'll reach out to this number within 24 hrs